|Last Price$140.38||Day Change (%)2.04%|
|Open Price$137.52||Day Change ($)2.80|
|Day Range136.38–140.38||52-Week Range127.10–242.37|
As of Thu 6/30/2016 5:14:00 PM | USD
Molecular Cytogenetics Market 2015-2022: Fluorescence In Situ Hybridization, Array-based Technology - Global Strategic Business Report 2016 - Research and Markets
Illumina Appoints Paula Dowdy Senior Vice President and General Manager of Commercial Operations for Europe, the Middle East and Africa
Xcell Biosciences to Present Data From its Avatar System at ISSCR Annual Meeting
Illumina ILMN reported second-quarter results Tuesday that beat our expectations, and we plan to raise our fair value estimate by several dollars per share. Revenue totaled $84.5 million for the quarter, a 103% increase from the year-ago period, which prompted the firm to significantly raise its ...
Continued technology advancements and market expansion support Illumina's narrow moat.
Tracy Murphy Joins Kilroy Realty Corporation as Executive Vice President
Competitive advantages have improved for Mead Johnson, while De La Rue's moat was downgraded to narrow and POSCO was deemed a no-moat company.
Recent deals have been driven more by tax strategies than therapeutic synergies.
Ownership data provide a look at who else owns the company.
While a majority of our top fund managers are outperforming this year, five of them truly stand out from the rest given their ability to outperform the market over all time periods.